Evidence map›Paper›PMID 30005686›Full record

ArticleBMC research notes2018

Caveolin-1 is dispensable for early lymphoid development, but plays a role in the maintenance of the mature splenic microenvironment.

Tyler A Herek, Jacob E Robinson, Tayla B Heavican, Catalina Amador, Javeed Iqbal, Christine E Cutucache

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tyler A HerekEppley Institute, University of Nebraska Medical Center, Omaha, NE, USA.
Jacob E RobinsonDepartment of Biology, University of Nebraska at Omaha, 6001 Dodge St, Omaha, NE, 68182, USA.
Tayla B HeavicanDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Catalina AmadorDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Javeed IqbalDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Christine E CutucacheDepartment of Biology, University of Nebraska at Omaha, 6001 Dodge St, Omaha, NE, 68182, USA. ccutucache@unomaha.edu.
University of Nebraska Medical Center · USUniversity of Nebraska at Omaha · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCaveolin-1 (CAV1) is known for its role as both a tumor suppressor and an oncogene, harboring a highly context-dependent role within a myriad of malignancies and cell types. In an immunological context, dysregulation of CAV1 expression has been shown to alter immunological signaling functions and suggests a pivotal role for CAV1 in the facilitation of proper immune responses. Nonetheless, it is still unknown how Cav1-deficiency and heterozygosity would impact the development and composition of lymphoid organs in mice. Herein, we investigated the impacts of Cav1-dysregulation on the lymphoid organs in young (12 weeks) and aged (36 weeks) Cav1

resultsWe observed that only Cav1-deficiency is associated with persistent splenomegaly at all timepoints. Furthermore, no differences in overall body weight were detected (and without sexual dimorphisms). Both aged Cav1

Indexed as

Signal TransductionAnimalsCaveolin 1Hematologic NeoplasmsHumansMiceNeoplasmsSplenomegalyCav1 protein, mouseCaveolin 1B cellCaveolin-1ImmunophenotypeSpleen

Identifiers

PMID30005686
PMCPMC6043983
OpenAlexW2884699468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.